Cargando…

Development of Coronavirus Treatments Using Neutralizing Antibodies

The Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus SARS-CoV-2, was first reported in December 2019 in Wuhan, Hubei province, China. This virus has led to 61.8 million cases worldwide being reported as of December 1st, 2020. Currently, there are no definite approved therapies en...

Descripción completa

Detalles Bibliográficos
Autores principales: Fouladirad, Saman, Bach, Horacio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7828509/
https://www.ncbi.nlm.nih.gov/pubmed/33451069
http://dx.doi.org/10.3390/microorganisms9010165
_version_ 1783641026596962304
author Fouladirad, Saman
Bach, Horacio
author_facet Fouladirad, Saman
Bach, Horacio
author_sort Fouladirad, Saman
collection PubMed
description The Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus SARS-CoV-2, was first reported in December 2019 in Wuhan, Hubei province, China. This virus has led to 61.8 million cases worldwide being reported as of December 1st, 2020. Currently, there are no definite approved therapies endorsed by the World Health Organization for COVID-19, focusing only on supportive care. Treatment centers around symptom management, including oxygen therapy or invasive mechanical ventilation. Immunotherapy has the potential to play a role in the treatment of SARS-CoV-2. Monoclonal antibodies (mAbs), in particular, is a relatively new approach in the world of infectious diseases and has the benefit of overcoming challenges with serum therapy and intravenous immunoglobulins preparations. Here, we reviewed the articles published in PubMed with the purpose of summarizing the currently available evidence for the use of neutralizing antibodies as a potential treatment for coronaviruses. Studies reporting in vivo results were summarized and analyzed. Despite promising data from some studies, none of them progressed to clinical trials. It is expected that neutralizing antibodies might offer an alternative for COVID-19 treatment. Thus, there is a need for randomized trials to understand the potential use of this treatment.
format Online
Article
Text
id pubmed-7828509
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78285092021-01-25 Development of Coronavirus Treatments Using Neutralizing Antibodies Fouladirad, Saman Bach, Horacio Microorganisms Review The Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus SARS-CoV-2, was first reported in December 2019 in Wuhan, Hubei province, China. This virus has led to 61.8 million cases worldwide being reported as of December 1st, 2020. Currently, there are no definite approved therapies endorsed by the World Health Organization for COVID-19, focusing only on supportive care. Treatment centers around symptom management, including oxygen therapy or invasive mechanical ventilation. Immunotherapy has the potential to play a role in the treatment of SARS-CoV-2. Monoclonal antibodies (mAbs), in particular, is a relatively new approach in the world of infectious diseases and has the benefit of overcoming challenges with serum therapy and intravenous immunoglobulins preparations. Here, we reviewed the articles published in PubMed with the purpose of summarizing the currently available evidence for the use of neutralizing antibodies as a potential treatment for coronaviruses. Studies reporting in vivo results were summarized and analyzed. Despite promising data from some studies, none of them progressed to clinical trials. It is expected that neutralizing antibodies might offer an alternative for COVID-19 treatment. Thus, there is a need for randomized trials to understand the potential use of this treatment. MDPI 2021-01-13 /pmc/articles/PMC7828509/ /pubmed/33451069 http://dx.doi.org/10.3390/microorganisms9010165 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Fouladirad, Saman
Bach, Horacio
Development of Coronavirus Treatments Using Neutralizing Antibodies
title Development of Coronavirus Treatments Using Neutralizing Antibodies
title_full Development of Coronavirus Treatments Using Neutralizing Antibodies
title_fullStr Development of Coronavirus Treatments Using Neutralizing Antibodies
title_full_unstemmed Development of Coronavirus Treatments Using Neutralizing Antibodies
title_short Development of Coronavirus Treatments Using Neutralizing Antibodies
title_sort development of coronavirus treatments using neutralizing antibodies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7828509/
https://www.ncbi.nlm.nih.gov/pubmed/33451069
http://dx.doi.org/10.3390/microorganisms9010165
work_keys_str_mv AT fouladiradsaman developmentofcoronavirustreatmentsusingneutralizingantibodies
AT bachhoracio developmentofcoronavirustreatmentsusingneutralizingantibodies